Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Msd K.k.

Russell R Ferlita

Robert Wenslow

Makoto Ishikawa

Joseph E Lynch

Nobuaki Nonoyama

Robert M Wenslow

Shinji Kato

Steven A Weissman

Toshihiro Wada

Yuji Haga

Christopher M Lindemann

Jerry Anthony Murry

Yaling Wang

Aaron J Moment

Karen C Thompson

Jinchu Liu

Alex Minhua Chen

Ralph Calabria

Karl Hansen

Andrey V Peresypkin

Robert M Wenslow, Jr

Nobuya Satake

Jian Wang

Yuri Y Bereznitski

Ashkan Kamali

Hisaki Kojima

David Mathre

Frederick T Mattrey

John L Leazer, Jr

Jungjun Yin

Ivan Lee

Yu Cheng

Stephen Howard Cypes

Kazuki Shigemori

Keisuke Kamei

Vicky K Vydra

Stephen Cypes

Evangelia Spartalis

Joseph D Armstrong

Alex M Chen

Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11&#x3b2;-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.

Crystalline forms of an inhibitor of 11-&#x3b2;-hydroxysteroid dehydrogenase type 1

The present invention relates to a process for producing N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof.

Crystalline forms of MC4R agonist and process for synthesis

The present invention relates to a process for producing crystalline trans-N-[1-(2-fluorophenyl)-S-pyrazoly]-3-ox-ospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4&#x2032;-carboxamide and novel salts, hydrates and polymorphs thereof.

Synthesis and crystalline forms of NPY5 antagonist

The present invention relates to a novel amorphous form of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-&#x3b1;]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of structural formula I as well as a process for its preparation, pharmaceutical compositions containing this novel form, and methods of use of the novel form and pharmaceutical compositions for the treatment of diabetes, obesity, and high blood pressure. 

Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor

The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.

Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor

Growing community of inventors

Westfield, NJ, United States of America

Russell R Ferlita